Skip to main content
All lobbying clients

OTSUKA AMERICA PHARMACEUTICAL, INC.

Lobbying client · Maryland · filed 2025 to 2026

Pharmaceutical Manufacturer.

$6,930,000 Reported spend
39 Filings counted
5 Outside firms hired
6 Bills named

Spend is reported income plus in-house expenses across 39 filings. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 6 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as OTSUKA AMERICA PHARMACEUTICAL, INC.

 Who filed for this client 6

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 6
  • H.R. 1
    One Big Beautiful Bill Act
    4 filings
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…
    4 filings
  • S. 832
    EPIC Act of 2025
    4 filings
  • H.R. 1518
    New Era of Preventing End-Stage Kidney Disease Act
    3 filings
  • H.R. 5509
    Safe Step Act
    2 filings
  • S. 2903
    Safe Step Act
    2 filings
 Reported by year 2 years
  • 2026 $2,300,000 15 filings
  • 2025 $4,630,000 24 filings
 Issues lobbied 8

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 2
  • HOUSE OF REPRESENTATIVES 38
  • SENATE 29
 Recent filings 39 total
Q3 report
TODD STRATEGY GROUP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View →
Q3 report
DB3, LLC (FKA THE DASCHLE GROUP)
3rd Quarter 2026 (July 1 - Sep 30) · House · $30,000 income · posted Oct 20, 2026
View →
Q3 report
W STRATEGIES, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · $50,000 income · posted Oct 19, 2026
View →
Q3 report
THORN RUN PARTNERS
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 19, 2026
View →
Q3 report
OTSUKA AMERICA PHARMACEUTICAL, INC.
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $310,000 expenses · posted Oct 15, 2026
View →
Q2 report
TODD STRATEGY GROUP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 20, 2026
View →
Q2 report
W STRATEGIES, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · $50,000 income · posted Jul 20, 2026
View →
Q2 report
THORN RUN PARTNERS
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 19, 2026
View →
Q2 report
DB3, LLC (FKA THE DASCHLE GROUP)
2nd Quarter 2026 (Apr 1 - June 30) · House · $30,000 income · posted Jul 17, 2026
View →
Q2 report
OTSUKA AMERICA PHARMACEUTICAL, INC.
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $1,240,000 expenses · posted Jul 16, 2026
View →
Q1 report
DB3, LLC (FKA THE DASCHLE GROUP)
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $30,000 income · posted Apr 20, 2026
View →
Q1 report
TODD STRATEGY GROUP
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 20, 2026
View →
Q1 report
W STRATEGIES, LLC
1st Quarter 2026 (Jan 1 - Mar 31) · House · $50,000 income · posted Apr 20, 2026
View →
Q1 report
THORN RUN PARTNERS
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 18, 2026
View →
Q1 report
OTSUKA AMERICA PHARMACEUTICAL, INC.
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $210,000 expenses · posted Apr 17, 2026
View →
Q4 report
TODD STRATEGY GROUP
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 20, 2026
View →
Q4 report
DB3, LLC (FKA THE DASCHLE GROUP)
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 20, 2026
View →
Q4 report
THORN RUN PARTNERS
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 20, 2026
View →
Q4 report
W STRATEGIES, LLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · $50,000 income · posted Jan 20, 2026
View →
Q4 termination
GOVERNMENT SOLUTIONS LLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $30,000 income · posted Jan 20, 2026
View →

Showing the 20 most recent of 39 filings. Search the explorer for "OTSUKA AMERICA PHARMACEUTICAL, INC.".

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem